首页 > 最新文献

Neurology and Neurobiology最新文献

英文 中文
An increase in corrected QT interval may indicate a good clinical response to amitriptyline in female patients with burning mouth syndrome 纠正后QT间期的增加可能表明阿米替林对女性灼口综合征患者有良好的临床反应
Pub Date : 2018-07-22 DOI: 10.31487/J.NNB.2018.10.005
Lou Mikuzuki, Yuma Aota, A. Toyofuku, Miho Takenoshita, T. Nagamine, T. Suga, Takeshi Watanabe, T. Tu
Burning mouth syndrome (BMS) is characterized by a burning sensation of the oral mucosa in the absenceof underlying causes. BMS patients can pose a therapeutic challenge to clinicians. Amitriptyline has been afirst-line treatment for BMS and is known to prolong corrected QT interval (QTc) in a dose dependentmanner. However, little is known about the QTc lengthening effect of amitriptyline at analgesic dosages.The objective of this study was to evaluate changes in QTc in female BMS patients treated withamitriptyline. We conducted a single-center retrospective observational study and evaluated 40 female BMSpatients. The QTc interval did not show statistically significant increase with amitriptyline (p=0.1502).However, the change in QTc of amitriptyline-responders was significantly longer than that of nonresponders (p=0.0142). The change in QTc may be a non-invasive maker of clinical responses toamitriptyline in female BMS patients.
灼口综合征(BMS)的特点是在没有根本原因的情况下,口腔黏膜有烧灼感。BMS患者可能对临床医生构成治疗挑战。阿米替林一直是BMS的一线治疗,并且已知以剂量依赖性方式延长校正QT间期(QTc)。然而,关于阿米替林在镇痛剂量下延长QTc的作用知之甚少。本研究的目的是评估阿米替林治疗的女性BMS患者QTc的变化。我们进行了一项单中心回顾性观察研究,评估了40名女性bmpatients。阿米替林组QTc间期增加无统计学意义(p=0.1502)。然而,阿米替林应答者的QTc变化明显长于无应答者(p=0.0142)。QTc的变化可能是女性BMS患者对阿米替林临床反应的非侵入性因素。
{"title":"An increase in corrected QT interval may indicate a good clinical response to amitriptyline in female patients with burning mouth syndrome","authors":"Lou Mikuzuki, Yuma Aota, A. Toyofuku, Miho Takenoshita, T. Nagamine, T. Suga, Takeshi Watanabe, T. Tu","doi":"10.31487/J.NNB.2018.10.005","DOIUrl":"https://doi.org/10.31487/J.NNB.2018.10.005","url":null,"abstract":"Burning mouth syndrome (BMS) is characterized by a burning sensation of the oral mucosa in the absence\u0000of underlying causes. BMS patients can pose a therapeutic challenge to clinicians. Amitriptyline has been a\u0000first-line treatment for BMS and is known to prolong corrected QT interval (QTc) in a dose dependent\u0000manner. However, little is known about the QTc lengthening effect of amitriptyline at analgesic dosages.\u0000The objective of this study was to evaluate changes in QTc in female BMS patients treated with\u0000amitriptyline. We conducted a single-center retrospective observational study and evaluated 40 female BMS\u0000patients. The QTc interval did not show statistically significant increase with amitriptyline (p=0.1502).\u0000However, the change in QTc of amitriptyline-responders was significantly longer than that of nonresponders (p=0.0142). The change in QTc may be a non-invasive maker of clinical responses to\u0000amitriptyline in female BMS patients.","PeriodicalId":19179,"journal":{"name":"Neurology and Neurobiology","volume":"131 10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87204323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term Efficacy and Safety of Donepezil Dose Escalation for Patients with Alzheimer?s Disease in a Clinical Setting 多奈哌齐剂量递增治疗阿尔茨海默病患者的长期疗效和安全性?临床环境中的疾病
Pub Date : 2018-06-08 DOI: 10.31487/j.NNB.2018.10.004
Laura Tan, Chathuri Yatawara, Debby Ng, N. Kandiah
Background: Donepezil is a routinely prescribed cognitive enhancer for patients with Alzheimer’s disease(AD), however the effectiveness and safety of long-term high doses remains largely unexplored.Objective: We investigated the long-term efficacy and safety of Donepezil dose escalation in reducingglobal cognitive decline for patients with AD in a clinical setting.Method: In a naturalistic, open-label, controlled study design, 71 mild to moderate AD patients from atertiary clinic were prescribed Donepezil 5mg/day for 12 months (phase 1), while 9 AD patients receivedno treatment. Patients who showed limited benefits (N=30) with Donepezil 5mg/day were titrated up to10mg/day for a subsequent 12 months (phase 2) and the remaining (N=41) patients continued on 5mg/day.The primary outcome was global cognition, indexed using the Mini-Mental State Examination (MMSE).Results: Phase 1 trends confirmed Donepezil 5mg/day was better than no treatment at reducing cognitivedecline (p = .09, f=.18). Phase 2 trends indicated that for patients who showed limited response to Donepezil5mg/day, Donepezil 10mg/day was more effective in reducing slope of cognitive decline (p = 0.13, f= .42).Additionally, the patients that were titrated up to 10mg/day had comparable treatment benefits to thosepatients that remained on 5mg/day during phase 2 (p = .32, f =.12). Side effects in the 10mg/day group werenot significantly different from the side effects in the 5mg group (t (67)=-1.27, p=.21).Conclusion: Donepezil dose escalation in patients with AD is safe and may result in large noticeable effectson cognition, with effects comparable to patients who initially responded well to 5mg/day.
背景:多奈哌齐是阿尔茨海默病(AD)患者的常规处方认知增强剂,但长期高剂量的有效性和安全性仍未得到充分研究。目的:在临床环境中,我们研究了多奈哌齐剂量递增在减少AD患者整体认知能力下降方面的长期有效性和安全性。方法:在一项自然、开放标签、对照研究设计中,来自二级诊所的71名轻中度AD患者服用多奈哌齐5mg/天,持续12个月(1期),而9名AD患者未接受治疗。服用多奈哌齐5mg/天疗效有限的患者(N=30)在随后的12个月(2期)中滴定至10mg/天,其余(N=41)患者继续服用5mg/天。主要结果是整体认知,使用迷你精神状态检查(MMSE)进行索引。结果:1期趋势证实多奈哌齐5mg/天在减少认知能力下降方面优于未治疗(p = 0.09, f= 0.18)。2期趋势表明,对于多奈哌齐尔5mg/天治疗反应有限的患者,多奈哌齐尔10mg/天在降低认知衰退斜率方面更有效(p = 0.13, f= 0.42)。此外,在第二阶段,滴定至10mg/天的患者与保持5mg/天的患者具有相当的治疗效果(p = 0.32, f = 0.12)。10mg/d组的副作用与5mg组的副作用无显著差异(t (67)=-1.27, p=.21)。结论:多奈哌齐剂量递增对AD患者是安全的,可能对认知产生显著的影响,其效果与最初服用5mg/d的患者相当。
{"title":"Long-term Efficacy and Safety of Donepezil Dose Escalation for Patients with Alzheimer?s Disease in a Clinical Setting","authors":"Laura Tan, Chathuri Yatawara, Debby Ng, N. Kandiah","doi":"10.31487/j.NNB.2018.10.004","DOIUrl":"https://doi.org/10.31487/j.NNB.2018.10.004","url":null,"abstract":"Background: Donepezil is a routinely prescribed cognitive enhancer for patients with Alzheimer’s disease\u0000(AD), however the effectiveness and safety of long-term high doses remains largely unexplored.\u0000Objective: We investigated the long-term efficacy and safety of Donepezil dose escalation in reducing\u0000global cognitive decline for patients with AD in a clinical setting.\u0000Method: In a naturalistic, open-label, controlled study design, 71 mild to moderate AD patients from a\u0000tertiary clinic were prescribed Donepezil 5mg/day for 12 months (phase 1), while 9 AD patients received\u0000no treatment. Patients who showed limited benefits (N=30) with Donepezil 5mg/day were titrated up to\u000010mg/day for a subsequent 12 months (phase 2) and the remaining (N=41) patients continued on 5mg/day.\u0000The primary outcome was global cognition, indexed using the Mini-Mental State Examination (MMSE).\u0000Results: Phase 1 trends confirmed Donepezil 5mg/day was better than no treatment at reducing cognitive\u0000decline (p = .09, f=.18). Phase 2 trends indicated that for patients who showed limited response to Donepezil\u00005mg/day, Donepezil 10mg/day was more effective in reducing slope of cognitive decline (p = 0.13, f= .42).\u0000Additionally, the patients that were titrated up to 10mg/day had comparable treatment benefits to those\u0000patients that remained on 5mg/day during phase 2 (p = .32, f =.12). Side effects in the 10mg/day group were\u0000not significantly different from the side effects in the 5mg group (t (67)=-1.27, p=.21).\u0000Conclusion: Donepezil dose escalation in patients with AD is safe and may result in large noticeable effects\u0000on cognition, with effects comparable to patients who initially responded well to 5mg/day.","PeriodicalId":19179,"journal":{"name":"Neurology and Neurobiology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88239407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hidden Factors in Diagnosing Alzheimer’s Disease 诊断阿尔茨海默病的隐藏因素
Pub Date : 2016-11-10 DOI: 10.15406/JNSK.2016.5.00176
Linda Maguire, Gary L. Kreps
Diagnoses of Alzheimer’s, dementia and other mental health conditions using the “family history method”can often be inaccurate, biased and possibly ill-motivated. Definitive clinical testing and/or biological testsrarely exist for most mental illnesses. Even when tests (such as PET scans or excess Abeta42 in cerebralspinal fluid indicating presence of neuronal plaques, for example) and other suggestive biomarkers are"positive", there are often no outward cognitive-behavioural symptoms or symptomatic evidence associatedwith the alleged mental illness (and vice-versa). Furthermore, environmental stressors, dehydration andother fully curable illness and treatable issues such as urinary tract infections, delirium, drug interactionsand insomnia can quickly create outward ‘false’ symptoms of mental illnesses, often mistaken for truemental health diagnoses. Therefore, a comprehensive consideration of ex parte narratives, experience,familiarity and also possible underlying motivations, of even the most well-meaning family members in the“family history method” of mental illness diagnoses, currently used by doctors and other professionals,should be revisited.
使用“家族史方法”诊断阿尔茨海默氏症、痴呆症和其他精神健康状况往往不准确、有偏见,而且可能动机不良。对于大多数精神疾病,明确的临床测试和/或生物学测试很少存在。即使测试(例如PET扫描或脑脊液中过量的Abeta42表明神经元斑块的存在)和其他暗示性生物标志物是“阳性”的,通常也没有与所谓的精神疾病相关的外部认知行为症状或症状证据(反之亦然)。此外,环境压力因素、脱水和其他完全可以治愈的疾病和可治疗的问题,如尿路感染、谵妄、药物相互作用和失眠,可以迅速产生精神疾病的外在“虚假”症状,经常被误认为是精神疾病的诊断。因此,在医生和其他专业人员目前使用的精神疾病诊断的“家族史方法”中,应该重新考虑即使是最善意的家庭成员的单方面叙述、经验、熟悉程度和可能的潜在动机。
{"title":"Hidden Factors in Diagnosing Alzheimer’s Disease","authors":"Linda Maguire, Gary L. Kreps","doi":"10.15406/JNSK.2016.5.00176","DOIUrl":"https://doi.org/10.15406/JNSK.2016.5.00176","url":null,"abstract":"Diagnoses of Alzheimer’s, dementia and other mental health conditions using the “family history method”\u0000can often be inaccurate, biased and possibly ill-motivated. Definitive clinical testing and/or biological tests\u0000rarely exist for most mental illnesses. Even when tests (such as PET scans or excess Abeta42 in cerebral\u0000spinal fluid indicating presence of neuronal plaques, for example) and other suggestive biomarkers are\u0000\"positive\", there are often no outward cognitive-behavioural symptoms or symptomatic evidence associated\u0000with the alleged mental illness (and vice-versa). Furthermore, environmental stressors, dehydration and\u0000other fully curable illness and treatable issues such as urinary tract infections, delirium, drug interactions\u0000and insomnia can quickly create outward ‘false’ symptoms of mental illnesses, often mistaken for true\u0000mental health diagnoses. Therefore, a comprehensive consideration of ex parte narratives, experience,\u0000familiarity and also possible underlying motivations, of even the most well-meaning family members in the\u0000“family history method” of mental illness diagnoses, currently used by doctors and other professionals,\u0000should be revisited.","PeriodicalId":19179,"journal":{"name":"Neurology and Neurobiology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88010070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurology and Neurobiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1